Biopharma & Life Sciences
Bruker Executive Compensation (FY25)
BRKR · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 21, 2026
314 figures on this page: 304 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Frank Laukien, Chairman, President and Chief Executive Officer, received $4,706,388 in total compensation for fiscal 2025, and for fiscal 2025, the company reported a chief executive pay ratio of 55:1, against median employee compensation of $85,571. Shareholders supported the say-on-pay proposal with 95.7% of votes cast for or against in favor at the meeting held May 21, 2026 for fiscal 2025. The disclosed peer group includes Agilent Technologies Inc., Avantor, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation and Charles River Laboratories International, Inc., among others. For fiscal 2025, the company reported 5 named executive officers.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Frank Laukien: $5,527,304 → $4,706,388 (14.9% lower)
Say-on-pay support: 94.8% → 95.7% (0.9 points higher)
CEO pay ratio: 73:1 → 55:1 (24.7% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Bruker's chief executive and what were they paid?
Frank Laukien, Chairman, President and Chief Executive Officer, received $4,706,388 in total compensation for fiscal 2025. Laukien's total was 14.9% lower than the $5,527,304 reported for fiscal 2024.
What was Bruker's say-on-pay result?
Shareholders supported the say-on-pay proposal with 95.7% of votes cast for or against in favor at the meeting held May 21, 2026 for fiscal 2025.
Which companies are in Bruker's peer group?
The disclosed peer group includes Agilent Technologies Inc., Avantor, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation and Charles River Laboratories International, Inc., among others.
What is Bruker's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 55:1, against median employee compensation of $85,571.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Frank H. Laukien Chairman, President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mark R. Munch Executive Vice President & President Bruker Nano Group | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Gerald N. Herman Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Juergen W. Srega President, Bruker CALID Group | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Falko Busse President, Bruker BioSpin Group | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Frank Laukien Chairman, President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mark Munch Executive Vice President & President, Bruker NANO Group | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Gerald Herman Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Juergen Srega President, Bruker CALID Group | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Falko Busse President, Bruker BioSpin Group | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Frank H. Laukien Chairman, President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mark R. Munch Executive Vice President & President, Bruker NANO Group | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Gerald N. Herman Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Juergen W. Srega President, Bruker CALID Group | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Falko Busse President, Bruker BioSpin Group | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Frank Laukien Chairman, President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mark Munch Executive Vice President and President, Bruker NANO Group | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Gerald Herman Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Juergen Srega President, Bruker CALID Group and Bruker Daltonics Division | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Falko Busse President, Bruker BioSpin Group | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Falko Busse | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Falko Busse | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Frank H. Laukien | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Frank H. Laukien | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Gerald N. Herman | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Gerald N. Herman | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Juergen W. Srega | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Juergen W. Srega | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mark R. Munch | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mark R. Munch | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Mark Munch | Option | ◇ | — | ◇ | 8/15/2035 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/09/2034 | |
| Option | ◇ | — | ◇ | 8/10/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/11/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Frank Laukien | Option | ◇ | — | ◇ | 8/15/2030 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/10/2028 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/09/2029 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/11/2027 | |
| Falko Busse | Option | ◇ | — | ◇ | 8/9/2034 |
| Option | ◇ | — | ◇ | 8/10/2033 | |
| Option | ◇ | — | ◇ | 8/11/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/15/2035 | |
| Juergen Srega | Option | ◇ | — | ◇ | 8/09/2034 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/10/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Gerald Herman | Option | ◇ | — | ◇ | 8/15/2035 |
| Option | ◇ | — | ◇ | 8/10/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/09/2034 | |
| Option | ◇ | — | ◇ | 8/11/2032 | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
John A. Ornell | ◇ | ◇ | — | — | — | — | ◇ |
Richard A. Packer Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Robert J. Rosenthal | ◇ | ◇ | — | — | — | — | ◇ |
Bonnie H. Anderson | ◇ | ◇ | — | — | — | — | ◇ |
William A. Linton | ◇ | ◇ | — | — | — | — | ◇ |
Adelene Q. Perkins | ◇ | ◇ | — | — | — | — | ◇ |
Cynthia M. Friend | ◇ | ◇ | — | — | — | — | ◇ |
Hermann F. Requardt | ◇ | ◇ | — | — | — | — | ◇ |
Laura A. Francis | ◇ | ◇ | — | — | — | — | ◇ |
Frank H. Laukien, John J. (Jack) Phillips and Thierry L. Bernard served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Agilent Technologies Inc. A
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bio-Techne Corporation TECH
- Charles River Laboratories International, Inc. CRL
- Entegris, Inc. ENTG
- Hologic, Inc. HOLX
- Illumina, Inc. ILMN
- Mettler Toledo International Inc. MTD
- MKS Instruments, Inc. MKSI
- Onto Innovation ONTO
- OSI Systems, Inc. OSIS
- Revvity, Inc. RVTY
- Teradyne, Inc. TER
- Waters Corporation WAT
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 21, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 29, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 30, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 7, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 1, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 4, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 21, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 20, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 21, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | May 22, 2017 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Bruker disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Bruker sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
314 figures on this page: 304 cited to the filing that reported them, 10 calculated from figures it prints.
304 cited to the filing
10 calculated from the filing
Documents cited
- 0001193125-26-234630
- 0001193125-26-1513052025 Grants of Plan-Based Awards · CEO Pay Ratio · DIRECTOR COMPENSATION · Director Compensation · and 2 more sections
- 0000950170-25-079029
- 0000950170-25-053286Summary Compensation Table
- 0000950170-24-066508
- 0000950170-24-046045Summary Compensation Table
- 0000950170-23-026851
- 0000950170-23-015837Summary Compensation Table
- 0001193125-22-165198
- 0001193125-21-184282
- 0001104659-20-065907
- 0001104659-19-030561
- 0001104659-18-034808
- 0001104659-17-034267
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Bruker executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BRKR (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Bruker and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Bruker discloses
The companies named in BRKR's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}